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Abstract
The role of the calcium binding protein, Calbindin 2 (CALB2), in regulating the response of colorectal cancer (CRC) cells to 5-
Fluorouracil (5-FU) was investigated. Real-time RT-PCR and Western blot analysis revealed that CALB2 mRNA and protein
expression were down-regulated in p53 wild-type and p53 null isogenic HCT116 CRC cell lines following 48 h and 72 h 5-FU
treatment. Moreover, 5-FU-induced apoptosis was significantly reduced in HCT116 and LS174T CRC cell lines in which
CALB2 expression had been silenced. Further investigation revealed that CALB2 translocated to the mitochondria following
5-FU treatment and that 5-FU-induced loss of mitochondrial membrane potential (Dym) was abrogated in CALB2-silenced
cells. Furthermore, CALB2 silencing decreased 5-FU-induced cytochrome c and smac release from the mitochondria and also
decreased 5-FU-induced activation of caspases 9 and 3/7. Of note, co-silencing of XIAP overcame 5-FU resistance in CALB2-
silenced cells. Collectively, these results suggest that following 5-FU treatment in CRC cell lines, CALB2 is involved in
apoptosis induction through the intrinsic mitochondrial pathway. This indicates that CALB2 may be an important mediator
of 5-FU-induced cell death. Moreover, down-regulation of CALB2 in response to 5-FU may represent an intrinsic mechanism
of resistance to this anti-cancer drug.
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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-
related deaths in Europe and the U.S.A. 5-Fluorouracil (5-FU)-
based chemotherapy regimens remain the standard treatment for
CRC in both the adjuvant and advanced disease settings.
However, response rates to 5-FU therapy are between 10–20%
in the metastatic setting [1]. The combination of 5-FU with the
topoisomerase I inhibitor, irinotecan (CPT-11), or the DNA-
damaging agent, oxaliplatin, has significantly improved response
rates up to 50% [2–3]. Novel agents, such as the monoclonal
antibodies cetuximab, panitumumab (epidermal growth factor
receptor inhibitors), and bevacizumab (a vascular endothelial
growth factor inhibitor) have also shown beneficial effects when
combined with chemotherapy [4–6]. Despite this, the prognosis
for the majority of patients with advanced CRC remains poor due
to intrinsic or acquired chemoresistance. Therefore, identification
of the signaling molecules involved in mediating the response of
CRC to 5-FU is required to determine the underlying mechanisms
of 5-FU resistance.
Calbindin-2 (CALB2, also known as calretinin) is a 29 kDa
calcium (Ca
2+) binding protein of the EF-hand family [7], which is
a family of proteins containing Ca
2+-binding motifs composed of
two helices (E and F). Ca
2+-induced conformational changes
suggest that CALB2 is likely to belong to a group of Ca
2+ sensor
proteins within this family [8]. In humans, CALB2 is primarily
expressed by certain cells of the nervous system, but can also be
found in ovarian cells [9]. Normal colon epithelial cells do not
express CALB2, but it is found in colon carcinomas [10], cell lines
derived from primary colon tumours [11] and it is a diagnostic
marker for mesotheliomas [12–13]. The role of CALB2 in
modulating neuronal excitability has been consistently demon-
strated [14]. However, the physiological function of CALB2 in
cancer cells remains to be elucidated.
Ca
2+ has been identified as a messenger that coordinates
endoplasmic reticulum (ER)-mitochondrial interactions that reg-
ulate apoptosis [15]. Many kinds of cellular stress are known to
induce Ca
2+ release from the ER and subsequent Ca
2+ influx into
the mitochondria resulting in loss of mitochondrial membrane
potential followed by release of cytochrome c and smac [16].
Induction of ER stress has also been reported to enhance
chemotherapy sensitization [17]. Mitochondrial Ca
2+ dynamics
are also involved in the regulation of cellular energy metabolism
and in processes such as cell motility and neurotransmitter release.
Therefore the regulation of Ca
2+ release is under tight control, and
many Ca
2+-binding proteins, such as CALB2, may function
downstream of the ER Ca
2+ release to modulate apoptosis or other
cell functions.
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HGU133 plus 2.0 array (Affymetrix, UK) examined the expression
profiles of p53
+/+ HCT116 CRC cells treated with 5-FU [18]. In
that study, CALB2 was identified as a potential novel regulator of 5-
FU response. The aim of this study was to investigate the
mechanismbywhichCALB2regulates5-FUresponseinCRCcells.
Materials and Methods
Reagents
5-FU was purchased from Sigma Chemical Co. (St. Louis, MO).
Stock solutions were prepared in sterile PBS and stored at 4uC prior
to use. The CALB2 antibody was purchased from Chemicon
International (Temecula, CA). Poly (ADP-ribose) polymerase
(PARP) antibody was purchased from PharMingen (San Diego,
CA, USA). Smac/DIABLO and Cytochrome c antibodies were
purchased from BD biosciences (Oxford, UK). Cytochrome c
oxidase sub unit IV (Cox IV) and X-linked inhibitor of apoptosis
protein (XIAP) antibodies were purchased from Cell Signaling
Technology, Inc (Danvers, MA, USA). Alpha-tubulin antibody was
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). GAPDH was purchased from AbD Serotec (Kidlington,
UK). Propidium iodide was purchased from Sigma (Poole, UK) and
FITC-Annexin V was purchased from BD biosciences (Oxford,
UK). Apan-caspase inhibitor,Z-VAD(OMe)-FMK, was purchased
from Calbiochem (Darmstadt, Germany).
Cell culture
Parental HCT116 and isogenic p53
2/2 and Bax
2/2 CRC cell
lines were kindly provided by Professor Bert Vogelstein (Johns
Hopkins University, Baltimore, MD). The LS174T cell line was
purchased from ATCCH (CL-188
TM). The HCT116 cell lines
were maintained in McCoy’s 5A medium (Invitrogen, UK) and
the LS174T cell line was maintained in Dulbecco’s Modified Eagle
Medium (Invitrogen, UK). Media was supplemented with 10%
dialysed foetal calf serum, 50 mg/ml penicillin-streptomycin,
2 mM L-glutamine and 1 mM sodium pyruvate and incubated
in 5% CO2 at 37uC.
Cell viability assay
Cell viability was determined by using a 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT, Sigma) assay as
described previously [19].
Real-time RT-PCR analysis
Total RNA was isolated using RNA STAT-60 reagent (Biogenesis,
Poole, UK) according to the manufacturer’s instructions. Reverse
transcription was carried out with 8 mgo fR N Au s i n gaM o l o n e y
Murine Leukaemia Virus (M-MLV) based reverse transcription kit
(Invitrogen, UK) according to the manufacturer’s instructions. Real-
time reverse transcription-PCR (RT-PCR) amplification was carried
out as described previously [18]. Primer sequences were as follows:
CALB2 (forward) 59-GCAGAGCTGGCGCAGATC- 39,C A L B 2
(reverse) 59-GCTCATCGTACGGCCGGTTCG- 39;G A P D H
(forward) 59 -ACAGTCAGCCGCATCTTCTT- 39 and GAPDH
(reverse) 59 - GACAAGCTTCCCGTTCTCAG -39.G e n ee x p r e s -
sion was normalised to expression of the GAPDH reference gene.
Final expression values were presented relative to the untreated time-
matched control.
Western blotting
Western blots were performed as previously described [19].
Immunodetection was performed using primary mouse monoclo-
nal antibodies against CALB2, PARP, Smac, cytochrome c,
XIAP, a-tubulin or GAPDH in conjunction with horseradish
peroxidise-conjugated sheep anti-mouse antibody (Amersham,
Little Chalfont, Buckinghamshire, England). A rabbit polyclonal
antibody against Cox IV was used in conjunction with a donkey
anti-rabbit secondary antibody (Amersham). The fluorescent
signal was detected using the Super Signal chemiluminescent
detection system (Pierce, Rockford, IL), according to the
manufacturer’s instructions.
Western blot protein quantification
Densitometry values of protein bands were acquired using the
ChemiDoc-XRS systems ship documentation system (Bio-Rad
Laboratories, Inc.). Bands were then analyzed using the Quantity
OneH1-D analysis software (Bio-Rad Laboratories, Inc., version,
4.5.2).
Analysis of subG1/G0
DNA content of cells was evaluated by propidium iodide (PI)
staining as described previously [18]. Measurements and analysis
were performed on a FACS Calibur flow cytometer with
CELLQUEST software (BD Biosciences, San Diego).
FITC Annexin V/Propidium Iodide analysis
Cells were harvested and analysed according to the manufac-
turer’s instructions (BD Biosciences, Oxford, UK). Briefly, levels of
apoptosis were calculated as the sum of FITC-Annexin V positive/
propidium iodide negative (early apoptosis) and FITC-Annexin V
positive/propidium iodide positive (late apoptosis) cell population.
Measurements and analysis were performed on a FACS Calibur
flow cytometer with CELLQUEST software (BD Biosciences, San
Diego).
Mitochondrial membrane potential analysis
To determine the loss of the mitochondrial membrane potential
(Dym), cells were incubated with 25 nM tetramethylrhodamine,
ethyl ester percholate (TMRE) at 37uC for 15 min and collected
by trypsinisation. Cells were pelleted by centrifugation at 800 g for
5 min at 4uC and resuspended in 0.5 ml PBS. Measurement and
analysis were performed on a FACS Calibur flow cytometer with
CELLQUEST software (BD Biosciences, San Diego).
siRNA transfection
The CALB2 targeting (siCALB2) and non-targeting control (SC)
siRNA constructs were purchased from Dharmacon Inc. (Chicago,
IL). The siCALB2 construct sequences used were GGCUCUGG-
CAUGAUGUCAAdTdT (sense) and UUGACAUCAUGCCA-
GAGCCdTdT (antisense). The SC construct sequences used were
UUCUCCGAACGUGUCACGUdTdT (sense) and ACGUGA-
CACGUUCGGAGAAdTdT (antisense). An additional 4 CAL-
B2-targeting siRNA sequence were purchased from Qiagen:
siCALB2_5 (SI02660980), siCALB2_6 (SI03190824), siCALB2_7
(SI04157790) and siCALB2_8 (SI04267697). Pre-designed siRNA
forXIAP waspurchasedfrom CellSignalling Technology(Danvers,
MA, USA). siRNA transfections were performed with Oligofecta-
mine reagent (Invitrogen) according to the manufacturer’s instruc-
tions. After 5 h, the cells were treated with parental ,IC60(72 h)
doses of 5-FU (5 mM for HCT116 and 20 mM for LS174T). Cells
were harvested following 72 h 5-FU treatment prior to analysis by
flow cytometry and Western blot.
Sub-cellular fractionation
Cells were collected by centrifugation, washed in 1 ml of ice-
cold mitochondrial isolation buffer (200 mM Mannitol, 70 mM
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1,N
1,
-tetraacetic acid, 10 mM HEPES, 0.5 mg/ml bovine serum
albumin; pH 7.4) prior to dounce homogenisation. Cell debris
was collected by centrifugation at 800 g for 10 min. the
mitochondrial fraction was pelleted by centrifugation at 10,000 g
for 10 min. The supernatant containing the cytosolic fraction was
transferred to a fresh tube and the mitochondrial pellet was
resuspended in 50 ml RIPA buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 5 mM EDTA, 1% Triton-X100, 0.1% SDS) containing
protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany).
Caspase Activation Assays
Caspase activation was measured using Caspase Glo 3/7, 8 and
9 assays (Promega) according to the manufacturer’s instructions.
Statistical analysis
Results were summarised as a mean 6 standard error of the
mean (SEM) of 3 independent experiments. The statistical
significance of the data was tested using a 2-way ANOVA
(GraphPad PRISMH version 5.01).
Microarray analysis
The 5-FU-resistant HCT116 sub-line was generated in our
laboratory as previously described [20]. HCT116 parental cells
and HCT116 5-FU resistant daughter cells were treated with
5 mM 5-FU for 24 h to identify genes that were differentially
expressed. Total RNA was isolated from the in vitro experiments
using the RNA STAT-60 Total RNA isolation reagent (Tel-Test)
according to the manufacturer’s instructions. Total RNA (5 mg)
was sent to Almac Diagnostics for cDNA synthesis, cRNA
synthesis, fragmentation, and hybridization onto the colorectal
Disease Specific Array (DSA, Almac Diagnostics) microarrays. All
in vitro assays were carried out in triplicate. All microarray data is
MIAME compliant and all raw data has been deposited in a
MIAME compliant database (ArrayExpress accession number: E-
MEXP-1691).
Generation of gene lists
Initially each array was normalized to the median signal
intensity of all arrays. For the drug treated arrays, the 24 h 5-FU
treated samples were then normalized to the untreated control
samples. In the case of the basal experiment, the 5-FU-resistant
arrays were normalized to the HCT116 parental arrays. All
microarray data (E-MEXP-1691) was then filtered using the
following criteria: Affymetrix flag calls (P/M in all samples), Cross
Gene Error Model (average base/proportional cut-off), fold
change (1.5-fold) and t test (p,0.05), only genes passing all 4
filters were retained and used as the final working genelists. Three
in vitro genelists were created: 5-FU-inducible in parental, 5-FU-
inducible in 5-FU-resistant and constitutively deregulated in 5-FU-
resistant.
Identification of pathways associated with 5-FU-
resistance
KEGG pathway function within Genespring GX (v7.3.1) was
used to identify deregulated pathways passing a 1.5 fold change
and t-test (p,0.05) from the microarray in vitro genelists.
Association of CALB2 expression with clinical response
We downloaded CALB2 expression data from public micro-
array data sets. GraphPad Prism 5 software was used to generate
Kaplan-Meier survival curves based on median CALB2 expression
across each tumour stage or combined staging. These data sets
included a CRC cohort (GSE12945; PMID: 19399471) of 62
patients (13 stage 1, 23 stage 2, 21 stage 3 and 5 stage IV)
undergoing elective standard oncological resection [21] and a
breast cancer cohort (GSE9893; PMID: 18347175) of 132
tamoxifen-treated patients) [22].
Results
CALB2 expression in HCT116 cells is down-regulated by
5-FU treatment
A previous microarray study by our group reported CALB2
gene expression in the HCT116 cell line to be up-regulated
following 24 h 5-FU treatment relative to an untreated 0 h control
[18]. However, further analyses revealed that constitutive CALB2
expression increases over time (Fig. S1), therefore we re-analysed
5-FU-induced mRNA changes in CALB2 gene expression levels
relative to an untreated, time-matched control. In contrast to our
previous study, this method indicated that treatment with an
,IC60(72 h) dose (5 mM) of 5-FU actually resulted in a significant,
time-dependent down-regulation of CALB2 gene expression in the
p53
+/+ HCT116 cell line (Fig. 1A). In the p53
2/2 HCT116 cell
line, CALB2 gene expression was not significantly altered after
24 h 5-FU treatment, but was significantly down-regulated at 48 h
and 72 h (Fig. 1B). Western blot analysis demonstrated that this
down-regulation was reflected in reduced CALB2 protein
expression in 5-FU treated cells (Fig. 1C). These results suggest
that CALB2 expression in HCT116 cells is acutely down-regulated
in response to 5-FU treatment and that this modulation is not
dependent on p53.
5-FU induced down-regulation of CALB2 is caspase-
independent
To determine whether the decrease in CALB2 protein in
response to 5-FU was caspase-dependent, HCT116 parental cells
were treated with an ,IC60(72 h) dose (5 mM) of 5-FU alone or in
combination with a 10 mM dose of a pan-caspase inhibitor (Z-
VAD) for 72 h. Inhibition of caspase activity following Z-VAD
treatment was validated using a caspase 3/7-specific activity assay
(Fig. 2A). 5-FU treatment significantly (p,0.05) increased caspase
3/7 activity by ,4 fold, compared to the untreated controls, and
this was completely abrogated by Z-VAD. Importantly, Z-VAD
co-treatment did not inhibit 5-FU-induced down-regulation of
CALB2 gene expression (Fig. 2B) or protein expression (Fig. 2C),
indicating that CALB2 down-regulation is not caspase-dependent.
CALB2 silencing confers 5-FU resistance
Since CALB2 is down-regulated following 5-FU treatment, we
investigated its role in mediating 5-FU-response. A gene silencing
approach was used to determine the function of CALB2 in 5-FU-
induced apoptosis. CALB2 knock down by siRNA was confirmed
by Western blot (Fig. 3A). siRNA-mediated silencing of CALB2
expression was further enhanced by 5-FU co-treatment, most
likely due to the suppression of CALB2 mRNA in response to 5-
FU treatment (Fig. 1A). PARP cleavage, an indicator of cell death,
was observed in the control siRNA-transfected p53
+/+ HCT116
cells following 5-FU treatment. This was completely abrogated in
the CALB2-silenced cells, indicating reduced 5-FU-induced death.
These results were supported by flow cytometry data which
indicated that the level of 5-FU-induced apoptosis was significantly
reduced (p,0.05) from ,30% in the siRNA control cells to ,17%
in the CALB2-silenced p53
+/+ HCT116 cells (Fig. 3B). In the
p53
2/2 HCT116 cell line, 5-FU-induced apoptosis was also
significantly reduced (p,0.05), from ,14% in the siRNA control
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sensitivity of p53
2/2 HCT116 cells to 5-FU has been previously
noted by our group and others [23,24]. Similar effects were
observed in another CRC cell line, LS174T, where apoptosis was
significantly increased following an ,IC60(72 h) dose of 20 mM5 -
FU and CALB2 silencing significantly reduced this (Fig. 3D,
p,0.01). CALB2 knock down was confirmed by Western blot
(Fig. 3D inset) and as in the HCT116 cell lines, CALB2 protein
levels were down-regulated following 5-FU treatment. To rule out
off-target effects of the CALB2-targeting siRNA, we used
Annexin/PI flow cytometry to determine the effect of an
additional 4 CALB2-targeting siRNA sequences on 5-FU-induced
apoptosis in the p53
+/+ HCT116 cells (Fig. 3E). A significant
reduction in 5-FU-induced apoptosis was observed with all 4
additional CALB2 siRNA sequences and CALB2 silencing was
confirmed by Western blot analysis (inset).
5-FU resistance is associated with de-regulation of Ca
2+
signalling
The identification of CALB2’s role in mediating 5-FU-induced
apoptosis together with its Ca
2+ binding property led us to
investigate the effect of 5-FU on Ca
2+ signalling in general.
Transcriptional profiling experiments were carried out in
Figure 1. 5-FU down-regulates CALB2 expression in HCT116 cell lines. Real-time RT-PCR quantification of CALB2 mRNA levels in isogenic (A)
p53
+/+ and (B) p53
2/2 HCT116 cells following 24 h, 48 h and 72 h 5-FU treatment (parental ,IC60(72 h) dose of 5 mM). Fold change in expression
values are relative to the untreated time-matched control. Error bars represent mean 6 SEM, NS: no significant difference, **p,0.01, ***p,0.001. (C)
Western blot analysis of CALB2 in HCT116 cell lines following 72 h 5-FU (5 mM) treatment and corresponding densitometry data of CALB2 expression
relative to the GAPDH loading control.
doi:10.1371/journal.pone.0020276.g001
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post-treatment with 5 mM 5-FU for 24 h. Microarray analysis
identified 1389 genes in the HCT116 parental cells and 922 genes
in the 5-FU-resistant daughter cells that were altered ($1.5-fold,
p,0.05) following 5-FU treatment. Also, 1329 genes were
identified as constitutively altered ($1.5-fold, p,0.05) between
the HCT116 parental cells and the 5-FU-resistant daughter cells.
The resultant genelists were then used for pathway analysis using
the KEGG pathway function within Genespring GX (v7.3.1).
Pathway analysis identified 60 pathways in the HCT116 parental
cells and 24 pathways in the 5-FU-resistant daughter cells that
were altered ($1.5-fold, p,0.05) following 24 h 5 mM 5-FU
treatment. Also, 49 pathways were identified as constitutively
altered ($1.5-fold, p,0.05) between the HCT116 parental cells
and the 5-FU-resistant daughter cells (Table S1). The results from
the pathway analysis demonstrated that 11 pathways were
commonly altered in each of the three genelists (Table 1). Of
particular relevance to the current study were the Ca
2+ signalling
and apoptosis pathways, which were altered in both the paren-
tal and 5-FU-resistant cells following 5-FU treatment and also
basally deregulated in 5-FU-resistant cells when compared to the
parentals. This suggests that Ca
2+ signalling and apoptosis may be
mediators of 5-FU sensitivity/resistance in this setting.
CALB2 silencing abrogates 5-FU-induced apoptosis
through the intrinsic pathway
Given the Ca
2+ binding properties of CALB2 and the integral
role of Ca
2+ signalling in the intrinsic apoptotic pathway, the role
of CALB2 in mediating 5-FU-induced, mitochondrial-regulated
apoptosis was investigated further. Examination of the HCT116
sub-cellular fractions demonstrated that in untreated cells, CALB2
was located in the cytosol and was not associated with the
mitochondria (Fig. 4A). However, following 72 h 5-FU treatment,
CALB2 levels in the cytosol decreased whilst mitochondrial
CALB2 levels increased, indicating 5-FU-induced CALB2 trans-
location to the mitochondria. Western blot analysis of a-tubulin
and CoxIV demonstrated the purity of these sub-cellular fractions
(Fig. S2). These results demonstrate an inducible association
between CALB2 and the mitochondria in response to 5-FU
treatment.
The association between CALB2 and the mitochondria
following 5-FU treatment prompted us to further investigate the
Figure 2. 5-FU-induced down-regulation of CALB2 is caspase-independent. p53
+/+ HCT116 cells were treated with an ,IC60(72 h) dose of 5-
FU alone or combined with a 10 mM dose of pan-caspase inhibitor Z-VAD (OMe)-FMK (Z-VAD) for 72 h (A) Caspase 3/7 activity was quantified using a
luciferase reporter based assay. Values are RFU read-outs relative to cell viability, as determined by MTT. (B) Real-time RT-PCR quantification of CALB2
mRNA (fold-change relative to the untreated, time-matched control). (C) Western blot analysis of CALB2 expression and corresponding densitometry
data of CALB2 expression relative to the GAPDH loading control.
doi:10.1371/journal.pone.0020276.g002
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+/+ HCT116 cell
line following transfection with control siRNA (2) or CALB2-targeting siRNA (+) and 72 h co-treatment with ,IC60(72 h) dose of 5-FU. GAPDH was
used as a loading control. Propidium Iodide flow cytometric analysis showing the percentage of cell population in sub-G1/G0 for (B) p53
+/+ and (C)
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pro-apoptotic Bcl-2 family member, Bax is an important initiator
of mitochondrial-mediated apoptosis. We therefore examined
HCT116 parental and isogenic Bax null cells following treatment
with the parental ,IC60(72 h) dose of 5-FU for 72 h. The parental
,IC60(72 h) dose of 5-FU caused an ,3-fold increase in apoptosis
in the HCT116 parental cell line (p,0.01), but had no significant
effect on levels of apoptosis in the Bax null cells (data not shown).
These results confirm previous findings [25,26] that Bax and the
intrinsic apoptotic pathway are major effectors of 5-FU-induced
apoptosis.
Loss of mitochondrial membrane potential (Dym) with con-
comitant release of smac and cytochrome c followed by caspase 9
and 3/7 activation is observed during apoptosis via the intrinsic
pathway. Therefore, TMRE, a fluorescent dye for measuring
membrane potential of mitochondria was used to determine Dym
by flow cytometry (Fig. 4B). 5-FU-induced loss of Dym,a s
indicated by non-fluorescent cells, was significantly reduced
(p,0.001) in the CALB2-silenced p53
+/+ HCT116 cells. 5-FU-
induced loss of Dym was also significantly reduced (p,0.05) in the
CALB2-silenced p53
2/2 cells. This effect was confirmed with a
second CALB2 siRNA sequence (Fig. 4C), ruling out off-target
effects of the CALB2 siRNA. In addition, Western blot analysis of
sub-cellular fractions revealed that 5-FU-induced loss of smac and
cytochrome c from the mitochondrial fraction was abrogated in
CALB2-silenced cells (Fig. 4D). This was concurrent with reduced
levels of smac and cytochrome c released into the cytosol in
response to 5-FU in the CALB2-silenced cells. Furthermore, 5-
FU-induced activation of caspase 9 and 3/7, as measured by
luciferase reporter-based activity assays, was significantly reduced
in the CALB2-silenced cells (Fig. 4E). No significant differences in
caspase 8 activation were observed between the CALB2-silenced
cells and siRNA controls following 72 h 5 mM 5-FU treatment
(data not shown). These results further suggest a role for CALB2 in
regulating the 5-FU-induced, intrinsic apoptotic pathway.
5-FU sensitivity in CALB2-silenced cells is restored by
XIAP co-silencing
The experiments described above demonstrate that maintenance
of mitochondrial membrane potential, retention of smac and
cytochrome c by the mitochondria with concomitant reduction in
caspase activity are all associated with increased 5-FU resistance in
CALB2-silenced cells, suggesting dysfunctional signalling via the
intrinsic apoptotic pathway. A previous study by our group
demonstrated that apoptosis resistance conferred by a compromised
intrinsic apoptotic pathway can be bypassed following XIAP
silencing. XIAP inhibits caspase 9 activation through its BIR3
domain and caspase 3 activation through its BIR2 domain. Smac
release disrupts the interaction of XIAP with caspase 9 and caspase 3
[27], leading to activation of these caspases and subsequent apoptosis.
We hypothesised that silencing XIAP may overcome resistance to 5-
FU caused by CALB2 silencing by bypassing the block in the intrinsic
apoptotic pathway. Therefore, the effect of co-silencing XIAP and
CALB2 on 5-FU response was investigated. XIAP silencing in
HCT116 cells using a XIAP-targeting siRNA was confirmed by
Western blot (Fig. 4F inset). The apoptotic fraction of cells was
identified by flow cytometry with Annexin V and propidium iodide.
This again demonstrated that 5-FU-induced apoptosis was signifi-
cantlyreduced (p,0.05) in CALB2-silenced cells(Fig. 4F) whereas, 5-
FU induced apoptosis was significantly increased in XIAP-silenced
cells (p,0.05). Importantly, the resistance to 5-FU-induced apoptosis
conferred by CALB2 silencing was overcome by co-silencing XIAP
Table 1. Pathways associated with 5-FU resistance.
Number of genes passing filter of 1.5 fold-change and p,0.05
Inducible parental Inducible resistant Constitutively de-regulated
Apoptosis 7 7 5
Calcium signalling 8 7 9
Cell cycle 21 13 11
Focal adhesion 16 13 10
Insulin signalling 20 12 8
MAPK signalling 19 14 12
Purine metabolism 19 12 17
Pyrimidine metabolism 9 12 10
Regulation of actin cytoskeleton 15 16 8
Tight junction 6 14 7
Wnt signalling 12 8 8
KEGG pathway analysis was used to identify pathways from 5-FU in vitro genelists and the pathways common to all genelists were selected. The 5-FU in vitro genelists
were: (1) genes induced by 5-FU in the sensitive HCT116 parentals (inducible parental), (2) genes induced by 5-FU in the 5-FU-resistant HCT116 sub-line (inducible
resistant) and (3) constitutively de-regulated genes in the 5-FU-resistant sub-line compared to the sensitive parentals (constitutively deregulated). Pathways contained
genes passing a 1.5 fold change and t-test (p,0.05).
doi:10.1371/journal.pone.0020276.t001
p53
2/2 HCT116 cells following transfection with control siRNA (SC) or CALB2 targeting siRNA (siCALB2) and 72 h co-treatment with 5 mM 5-FU. (D)
Annexin V/propidium iodide flow cytometric analysis of the LS174T CRC cell line following transfection with control siRNA (SC) or CALB2 targeting
siRNA (siCALB2) and 72 h co-treatment with ,IC60(72 h) dose of 5-FU (20 mM). ** p,0.01, error bars represent mean 6 SEM. (Inset) Western blot
analysis of CALB2 expression in LS174T. GAPDH was used as a loading control. (E) p53
+/+ HCT116 cells following transfection with control siRNA (SC),
CALB2 targeting siRNA (siCALB2) or additional CALB2-targeting siRNA sequences (siCALB2_5, siCALB2_6, siCALB2_7 and siCALB2_8) and 72 h co-
treatment with 5 mM 5-FU. (Inset) Western blot analysis of CALB2 expression following 72 h transfection with control siRNA (SC) or CALB2 targeting
siRNAs in p53
+/+ HCT116 cells. a-tubulin was used as a loading control.
doi:10.1371/journal.pone.0020276.g003
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20276(p,0.01). Of note, CALB2 silencing did not affect XIAP levels (Fig.
S3). These results suggest that XIAP silencing abrogates 5-FU
resistance caused by CALB2 silencing.
CALB2 expression in CRC patients
Given the pro-apoptotic function of CALB2 in CRC cell lines,
we used a public CRC data set to determine whether CALB2
expression was associated with patient prognosis (Fig. 5). CALB2
expression in the CRC GSE12945 dataset (PMID: 19399471;
probe ID: 20542 s at) was analysed for stage 3 tumours and
combined staging. A non-significant trend for high CALB2
expression correlating with increased overall survival was observed
in all patients (HR=2.507; 95% CI of ratio=0.8066–7.793;
p=0.1122; n=62) and the later stage patients (p value=0.3057;
n=26, includes 21 stage 3 and 5 stage 4 patients). This data
suggests a potential association between CALB2 and patient
outcome, however this would require validation in a large
independent CRC patient cohort.
The association between CALB2 expression and patient
survival was also examined in the GSE9893 breast cancer dataset
(PMID: 18347175). In this data set (132 patients), high CALB2
expression (probe ID: 20864) was significantly associated with
increased overall survival (hazard ratio 1.86; 95% CI of
ratio=1.054–3.285; minimum p value=0.001826; corrected p
value=0.0322, Fig. S3), suggesting that CALB2 expression may
have a prognostic role in this disease.
Discussion
We previously identified CALB2 as a potential regulator of 5-
FU resistance following a DNA microarray profiling experiment
[18]. The aim of this study was to further investigate the role of
CALB2 in regulating 5-FU response in CRC cells. CALB2
transcription and protein expression were down-regulated in p53
wild-type (WT) and null HCT116 cell lines following 5-FU
treatment Down-regulation of CALB2 expression was not
abrogated by the pan-caspase inhibitor Z-VAD, demonstrating
that this process is independent of caspase activity.
In order to determine the role of CALB2 in the regulation of 5-
FU response, gene silencing studies were conducted. CALB2
silencing significantly increased 5-FU resistance in the HCT116
cell lines, both p53 WT and null, and the LS174T cell line which is
p53 WT, but does not express p53 (www.lgcstandards-atcc.org).
These results indicate a pro-apoptotic role for CALB2 in 5-FU-
mediated cell death and demonstrate that this process may be
independent of p53 status. In vitro studies based on neuroprotec-
tion, report contradictory roles for CALB2, with some studies
suggesting an anti-apoptotic role and others reporting no effect. In
the P19 murine model, cells that were stably transfected with
CALB2 cDNA exhibited delayed onset of cell death induced by
excitotoxic stimulation [28]. A follow-on study using an N18-RE
105 neuroblastoma-retina hybrid model, demonstrated that cells
stably transfected with CALB2 cDNA were protected from Ca
2+-
dependent L-glutamate-induced cytotoxicity [29]. In contrast to
the protective role of CALB2, a lack of protection from Ca
2+
overload and trophic factor deprivation was reported in rat PC12
cells with either exogenous or endogenous CALB2 expression
[30]. The present study proposes a pro-apoptotic role for CALB2
which may highlight cancer-specific functions for CALB2 that are
relevant in the context of chemotherapy treatment. In addition,
acute down-regulation of CALB2 in response to 5-FU treatment
may represent a mechanism of 5-FU resistance in cancer cells.
Figure 5. CALB2 expression in CRC patients. Kaplan-Meier survival curves for CALB2 expression across a CRC patient cohort (Dataset: GSE12945,
probe ID: 20542 s at, n=62). CALB2 expression and patient survival were analysed for stage 3 patients (n=26, includes 5 stage 4 patients) and
combined stage tumours (n=62). The red line shows patients with high CALB2 expression and the blue line shows patients with low CALB2
expression. High and low level expression cut-points were based on median CALB2 expression.
doi:10.1371/journal.pone.0020276.g005
Figure 4. Increased 5-FU resistance in CALB2 silenced cells is associated with abrogated induction of the intrinsic apoptotic
pathway. (A) Western blot analysis of CALB2 in the mitochondrial and cytosolic fractions of p53
+/+ HCT116 cells following transfection with control
siRNA (2) or CALB2-targeting siRNA (+) and 72 h co-treatment with 5-FU. Cox IV was used as a mitochondrial loading control and a-tubulin was used
as a cytosolic loading control. (B) TMRE flow cytometric analysis showing the percentage of isogenic p53
+/+ and p53
2/2 HCT116 cells with loss of
Dym (% depolarised) following transfection with control siRNA (sc) or CALB2 targeting siRNA (siCALB2) and 72 h co-treatment with 5 mM 5-FU.
**p,0.01, error bars represent mean 6 SEM. (C) TMRE flow cytometry experiment repeated with a second siCALB2 sequence. (D) Western blot
analysis of smac and cytochrome C in the mitochondrial and cytosolic fractions of 5-FU treated p53
+/+ HCT116 cells. Cox IV and a-tubulin were used
as loading controls. (E) Caspase activity assays in p53
+/+ HCT116 cells. RFU values were normalised to cell viability (MTT assay) and expressed as fold-
change RFU in the CALB2 silenced cells relative to the siRNA control (SC) cells. Error bars represent the mean 6 SEM. (F) Annexin V/propidium iodide
flow cytometric analysis of apoptotic p53
+/+ HCT116 cells following CALB2 or XIAP silencing alone or in combination. Cells were co-treated with 5 mM
5-FU for 72 h as indicated. *p,0.05, **p,0.01, error bars represent mean 6 SEM. (Inset) Western blot analysis of XIAP expression following
transfection with 10 nM control siRNA (2) or 10 nM XIAP targeted siRNA (+). GAPDH was used as a loading control.
doi:10.1371/journal.pone.0020276.g004
CALB2 Regulates 5-FU-Induced Apoptosis in CRC
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20276Having identified CALB2 as a modifier of 5-FU sensitivity, the
mechanism by which CALB2 silencing confers 5-FU resistance was
investigated. Given the Ca
2+ binding property of CALB2, we
hypothesisedthat Ca
2+signallingisimportantinmediating response
of CRC cells to 5-FU. Pathway analysis of microarray data from the
HCT116 in vitro model indicated that the Ca
2+ signalling and
apoptosis pathways were altered in the 5-FUresistant HCT116 cells
compared to the 5-FU sensitive parentals. Since Ca
2+-mediated
crosstalk between the ER and the mitochondria determines the
balance between cell survival and mitochondrial-mediated cell
death [16], these findings prompted us to investigate the role of
CALB2 in the intrinsic apoptotic pathway.
CALB2 was found to translocate to the mitochondria following
5-FU treatment suggesting a role in regulating Ca
2+ signalling to
the mitochondria. The present study also demonstrated that 5-FU
sensitivity was compromised in the Bax
2/2 cells compared to the
parental HCT116 cells (data not shown). This further confirms a
role for the intrinsic apoptotic pathway in 5-FU resistance and is in
agreement with previous studies [25,26].
Loss of mitochondrial membrane potential (Dym) followed by
release of mitochondrial pro-apoptotic proteins such as smac and
cytochrome c into the cytosol is a critical step during mitochon-
drial-regulated apoptosis [31] and leads to caspase activation. We
demonstrated that CALB2 silencing inhibits this cascade of events
induced by 5-FU treatment and implicate CALB2 as a positive
mediator of the intrinsic apoptotic pathway. 5-FU sensitivity was
restored upon XIAP co-silencing in CALB2-silenced cells. This is
in agreement with a previous study by our group [26] which used
the Bax
2/2 cells to show that XIAP silencing could re-sensitise
cells with a dysfunctional intrinsic apoptotic pathway to FLIP
silencing. This result further suggests dysfunctional intrinsic
apoptotic signalling as a mechanism for 5-FU resistance in
CALB2-silenced cells.
Given the pro-apoptotic function of CALB2, we hypothesised
that cancer patients with higher levels of CALB2 would have a
better prognosis. Investigation of CALB2 expression levels in
patients within a CRC cohort [21] showed that patients with high
levels of CALB2 had a better overall survival, although this was
not significant (p=0.1122). When sub-divided according to
tumour stage, this trend was also observed in stage 3 patients.
Despite the lack of chemotherapy information available for this
cohort, it is likely that the stage 3 patients will have received 5-FU
based chemotherapy and this may therefore suggest an association
of CALB2 expression with 5-FU response. High CALB2 levels
were also associated with better overall survival in a breast cancer
cohort treated with tamoxifen and radiotherapy [22] (Fig. S4,
p=0.0322). Overall, these results are consistent with our findings
that CALB2 has a pro-apoptotic role following chemotherapy and
suggests that CALB2 may be a potentially useful prognostic
biomarker. However, this would require substantial verification.
In conclusion, this study identifies a novel role for CALB2 as a
modulator of 5-FU-induced death in CRC cells through activation
of the intrinsic apoptotic pathway.
Supporting Information
Figure S1 CALB2 gene expression in untreated HCT116
cells. Real-time RT-PCR quantification of CALB2 mRNA levels
in untreated p53
+/+ HCT116 cells following 24 h, 48 h and 72 h
culture. Fold change in expression values are relative to the
untreated 0 h control. Error bars represent mean 6 SEM,
**p,0.01.
(TIF)
Figure S2 Western blot analysis of CoxIV and a-tubulin
levels in p53
+/+ HCT116 mitochondrial and cytosolic
fractions.
(TIF)
Figure S3 Western blot analysis of XIAP expression
following 72 h transfection with 5 nM control siRNA (2)
or CALB2 targeted siRNA (+). GAPDH was used as a
loading control.
(TIF)
Figure S4 CALB2 expression in breast cancer. Kaplan-
Meier survival curve across a breast cancer patient cohort
(Dataset: GSE9893, probe ID: 20864; n=132; HR=1.861; CI
of ratio=1.054–3.285; p=0.0322; n=132). The red line shows
patients with high CALB2 expression and the blue line shows
patients with low CALB2 expression. High and low level
expression cut-points were based on median CALB2 expression.
(TIF)
Table S1 Identification of de-regulated pathways asso-
ciated with 5-FU resistance by pathway analysis. KEGG
pathway analysis was used to identify pathways associated with 5-
FU resistance from the 5-FU in vitro genelists: (1) genes induced by
5-FU in the sensitive HCT116 parentals (inducible parental), (2)
genes induced by 5-FU in the 5-FU-resistant HCT116 sub-line
(inducible resistant) and (3) constitutively de-regulated genes in the
5-FU-resistant sub-line compared to the sensitive parentals
(constitutively deregulated). All pathways contained $5 genes
passing a 1.5 fold change and t-test (p,0.05).
(DOCX)
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